JPS62294968A - Diagnosing drug comprising monoclonal antibody - Google Patents
Diagnosing drug comprising monoclonal antibodyInfo
- Publication number
- JPS62294968A JPS62294968A JP13827986A JP13827986A JPS62294968A JP S62294968 A JPS62294968 A JP S62294968A JP 13827986 A JP13827986 A JP 13827986A JP 13827986 A JP13827986 A JP 13827986A JP S62294968 A JPS62294968 A JP S62294968A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- monoclonal antibody
- diagnosing drug
- antibody method
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract 5
- 229940079593 drug Drugs 0.000 title claims abstract 5
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims abstract description 10
- 229920000288 Keratan sulfate Polymers 0.000 claims description 10
- 238000000034 method Methods 0.000 abstract description 19
- 210000001519 tissue Anatomy 0.000 abstract description 8
- 102000004190 Enzymes Human genes 0.000 abstract description 4
- 108090000790 Enzymes Proteins 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 239000000427 antigen Substances 0.000 abstract description 2
- 102000036639 antigens Human genes 0.000 abstract description 2
- 108091007433 antigens Proteins 0.000 abstract description 2
- 238000008416 Ferritin Methods 0.000 abstract 2
- 102000008857 Ferritin Human genes 0.000 abstract 2
- 108050000784 Ferritin Proteins 0.000 abstract 2
- 210000002808 connective tissue Anatomy 0.000 abstract 2
- 229910001385 heavy metal Inorganic materials 0.000 abstract 1
- 238000002372 labelling Methods 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 description 8
- 239000000032 diagnostic agent Substances 0.000 description 8
- 210000000845 cartilage Anatomy 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 208000018631 connective tissue disease Diseases 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- KVIYXIWBXOQZDN-UHFFFAOYSA-N [3-(phenylcarbamoyl)naphthalen-2-yl] dihydrogen phosphate Chemical compound OP(O)(=O)OC1=CC2=CC=CC=C2C=C1C(=O)NC1=CC=CC=C1 KVIYXIWBXOQZDN-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000987 azo dye Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000015100 cartilage disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
３、発明の詳細な説明
［産業上の利用分野］
本発明は、モノクローナル抗体からなる診断用薬剤に関
し、更に詳しくは、ケラタン硫酸の含量０種類の変動を
伴う各種の結合組織の疾患の診断に有用な、ケラタン硫
酸に対するモノクローナル抗体からなる診断用薬剤に関
する。Detailed Description of the Invention 3. Detailed Description of the Invention [Industrial Field of Application] The present invention relates to a diagnostic agent comprising a monoclonal antibody, and more specifically, the present invention relates to a diagnostic agent consisting of a monoclonal antibody. The present invention relates to a diagnostic agent comprising a monoclonal antibody against keratan sulfate, which is useful for diagnosing connective tissue diseases.
［従来技術及びその問題点」
グラタン硫酸の分布と性質の変化が重要な意義を有する
とされているが、詳細は不明である。[Prior art and its problems] Changes in the distribution and properties of gratan sulfate are said to have important significance, but the details are unknown.
従来、ケラタン硫酸の組織学的検索においては特異的に
染色する方法がなかった。即ち、ケラタン硫酸以外のム
コ多糖を分解する種々の酵素を用いて前処理した後、ト
ルイジン、ブルー、アルシャンブルー等のムコ多糖染色
法により識別していた。この方法では、操作法が繁雑な
上に各組織における酵素反応条件の検討、各研究者の手
技上の相違等が加わり、特異的で正確なケラタン硫酸の
識別ができなかった。特に、グラタン硫酸をヘパラン硫
酸、ヘパリンと染色し分けることが困難であった（大高
裕−著：結合組織病、第８８頁、金属出版■、１９８４
年）。Until now, there was no specific staining method for histological examination of keratan sulfate. That is, after pretreatment with various enzymes that decompose mucopolysaccharides other than keratan sulfate, they were identified by mucopolysaccharide staining methods such as toluidine, blue, and Alcian blue. With this method, in addition to the complicated procedures, consideration of enzyme reaction conditions for each tissue and differences in the techniques of each researcher were added, making it impossible to identify keratan sulfate specifically and accurately. In particular, it was difficult to stain and distinguish gratan sulfate from heparan sulfate and heparin.
Year).
本発明者らは、ケラタン硫酸を特異的に正確に識別でき
れば、各種疾患の診断が可能になると考え、鋭意研究を
重ねた結果、本発明を完成するに至った。The present inventors believe that if keratan sulfate can be specifically and accurately identified, it will be possible to diagnose various diseases, and as a result of extensive research, they have completed the present invention.
［発明の構成］
本発明は、グラタン硫酸に対するモノクローナル抗体か
らなることを特徴とする診断用薬剤に関するものである
。[Structure of the Invention] The present invention relates to a diagnostic agent characterized by comprising a monoclonal antibody against gratan sulfate.
本発明に用いるモノクローナル抗体は、グラタン硫酸を
抗原として用い、通常のモノクローナル抗体の製法１例
えばカターソンらの方法［Ｔｈｅ Ｊｏｕｒｎａｌ ｏ
ｆ Ｂｉｏｌｏｇｉｃａｌ Ｃｈｅｍｉｓｔｒｙ、 ２
５８ 。The monoclonal antibody used in the present invention uses gratan sulfate as an antigen and is produced by a conventional monoclonal antibody production method 1, for example, the method of Catterson et al. [The Journal
f Biological Chemistry, 2
58.
８８４８ （１９８３）］に従うことにより製造する
ことができる。8848 (1983)].
また、該抗体はマイルス・ラボラトリーズ・インコーホ
レーテッド（以下ｒマイルス社」という）から市販され
ている。Further, the antibody is commercially available from Miles Laboratories, Inc. (hereinafter referred to as "R-Miles").
本発明の診断用薬剤を各種疾患の診断に用いるには、次
のようにして行えばよい。The diagnostic agent of the present invention can be used in the diagnosis of various diseases as follows.
即ち、検体として被検者からバイオプシーなどにより取
り出した組織片を本発明の診断用薬剤で処理して診断用
薬剤（モノクローナル抗体）の組織片への結合状態を観
察することにより各種疾患の診断を行うことができる。That is, various diseases can be diagnosed by treating a tissue piece taken out from a subject by biopsy or the like as a specimen with the diagnostic agent of the present invention and observing the state of binding of the diagnostic agent (monoclonal antibody) to the tissue piece. It can be carried out.
本発明で対象となる疾患は、病態組織においてケラタン
硫酸の分布が正常組織のそれと異なる全ての結合組織の
疾患であり、４．νに結合組織病、例えば変形性関節症
（以下「ＯＡ」という）、慢性関節リウマチ（以下「Ｒ
Ａ」という）、全身性エリテマトーデスが挙げられるが
、他の骨・軟骨疾患（椎間板ヘルニア、骨腫瘍、変敗症
、骨頭壊死など）、動脈硬化症、骨粗浮症などの疾患も
対象となりうる。The diseases targeted by the present invention are all connective tissue diseases in which the distribution of keratan sulfate in pathological tissues differs from that in normal tissues; 4. ν is associated with connective tissue diseases such as osteoarthritis (hereinafter referred to as "OA") and rheumatoid arthritis (hereinafter referred to as "R").
A), systemic lupus erythematosus, but other bone and cartilage diseases (disc herniation, bone tumors, degenerative diseases, bone head necrosis, etc.), arteriosclerosis, osteoporosis, and other diseases can also be targeted. .
前記モノクローナル抗体の組織片への結合状態を観察す
る手段としては、直接法、間接法のいずれを用いてもよ
く、酵素抗体法、蛍光抗体法、フェリチン抗体法、重金
属標識抗体法、非標識酵素抗体法などを利用することが
できる。As a means for observing the binding state of the monoclonal antibody to the tissue piece, either a direct method or an indirect method may be used. Antibody methods etc. can be used.
［発明の効果］
本発明によれば、各種の結合組織の疾患を有効に診断す
ることができる。[Effects of the Invention] According to the present invention, various connective tissue diseases can be effectively diagnosed.
［発明の実施例］
以下、実施例により本発明を更に詳細に説明するが、こ
れらの実施例は本発明の範囲を何ら制限するものではな
い。[Examples of the Invention] Hereinafter, the present invention will be explained in more detail with reference to Examples, but these Examples are not intended to limit the scope of the present invention in any way.
実施例
材料及び方法：
正常人、ＯＡ患者、ＲＡ思者各２例の軟骨のケラタン硫
酸に対するモノクローナル抗体による免疫組織学的検索
を行った。各軟骨標本は関節鏡により、又は手術時に少
量採取し、常法に従って酵素抗体法により染色した。免
疫組織化学的検索は、次の手順によって行った。Examples Materials and Methods: Immunohistological examination of the cartilage of two cases each of normal subjects, OA patients, and RA patients was performed using a monoclonal antibody against keratan sulfate. A small amount of each cartilage specimen was taken arthroscopically or during surgery, and stained using an enzyme antibody method according to a conventional method. Immunohistochemical search was performed by the following procedure.
１、 Ｐ Ｌ Ｐ（ｐｅｒｉｏｄａｔｅ−１７
ｓｉｎｓ−ｐａｒａｆｏｒｍａｌｄｅｈｙｄｅ）固定液
で４℃において一夜処理
２、リン酸緩衝食塩水（以下ｒＰＢＳＪという）で洗浄
３、脱水系列（クロロホルム使用）
４、パラフィン包埋
５、パラフィン切片
６、脱パラフィン及びアルコール系列
７、蒸留水にて洗浄（５分）
８．０．３％ Ｈ２Ｏ２加メタノール中に浸せき（３０
分）
９、ＰＢＳで洗浄（２０分）
１０、ＰＢｓで希釈した正常ヤギ血清でインキュベーシ
ョン（２０分）
１１、ＰＢＳで洗浄
１２、−次抗体（マイルス社製モノクローナル抗ケラタ
ン硫酸抗体）でインキュベーション（３０分）
＋３．ＰＢＳで洗浄（１０分）
！４．二次抗体（ダコ社製アルカリホスファターゼ標識
化抗マウスＩｇＧ抗体）でインキュベーション
＋５．ＰＢＳで洗浄
１Ｇ、ナフトールＡＳホスフェートを基質に用いるアゾ
色素法により発色
１７、ＰＢＳで洗浄
１日、ヘマトキシリンで核染色
１９、水で洗浄
２０、封入
染色性の評価：
軟骨表層は採取上の問題や病態との関係で判別しにくい
ことから、中間層及び深層における染色性の変化を細胞
内領域（ａ）、細胞周辺領域（ｂ）、細胞間領域（Ｃ）
において５段階（０゜０．５，１．１．５．２）に分け
て評価した。1, PLP (periodate-17
(sin-paraformaldehyde) fixative at 4°C overnight 2. Washing with phosphate buffered saline (hereinafter referred to as rPBSJ) 3. Dehydration series (using chloroform) 4. Paraffin embedding 5. Paraffin sectioning 6. Deparaffinization and alcohol series 7. Wash with distilled water (5 minutes) 8. Soak in methanol containing 0.3% H2O2 (30 minutes)
9. Wash with PBS (20 minutes) 10. Incubate with normal goat serum diluted in PBs (20 minutes) 11. Wash with PBS 12. Incubate with the following antibody (monoclonal anti-keratan sulfate antibody manufactured by Miles) (30 minutes) minutes) +3. Wash with PBS (10 minutes)! 4. Incubation with secondary antibody (alkaline phosphatase-labeled anti-mouse IgG antibody manufactured by Dako) +5. Washed with PBS for 1G, developed color using the azo dye method using naphthol AS phosphate as a substrate (17), washed with PBS for 1 day, nuclear staining with hematoxylin (19), washed with water (20), evaluation of encapsulation staining: The surface layer of the cartilage was removed due to problems in collection. Since it is difficult to distinguish in relation to the pathological condition, changes in staining in the intermediate and deep layers are shown in the intracellular region (a), the pericellular region (b), and the intercellular region (C).
The evaluation was divided into five stages (0°0.5, 1.1.5.2).
結果： 結果を表１に示す。result: The results are shown in Table 1.
表１から明らかなように、正常軟骨、ＲＡ軟骨及びＯＡ
軟骨のモノクローナル抗ケラタン硫酸抗体による染色性
は下記のような差異が認められた。As is clear from Table 1, normal cartilage, RA cartilage and OA
The following differences were observed in staining of cartilage with monoclonal anti-keratan sulfate antibody.
細胞内領域における染色性＝ＯＡ≧ＲＡ、正常細胞周辺
領域における染色性＝ＯＡ〉正常、ＲＡ細胞間領域にお
ける染色性：ＯＡ、ＲＡ≧正常また、ＯＡ軟骨における
特徴的な所見として、中間層の細胞辺縁から周辺にかけ
て柱状に強く染色されているのが散見された。Stainability in the intracellular region = OA≧RA, normal Stainability in the surrounding cell area = OA>normal, RA stainability in the intercellular region: OA, RA≧normal Also, as a characteristic finding in OA cartilage, the intermediate layer Strong columnar staining was observed from the cell edge to the periphery.
以上のことから、本発明の診断用薬剤を用いることによ
り、ＯＡとＲＡの病態識別が可能であることが判明した
。From the above, it has been found that the pathological conditions of OA and RA can be distinguished by using the diagnostic agent of the present invention.
Claims (1)
を特徴とする診断用薬剤。A diagnostic drug characterized by comprising a monoclonal antibody against keratan sulfate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13827986A JPS62294968A (en) | 1986-06-16 | 1986-06-16 | Diagnosing drug comprising monoclonal antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13827986A JPS62294968A (en) | 1986-06-16 | 1986-06-16 | Diagnosing drug comprising monoclonal antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS62294968A true JPS62294968A (en) | 1987-12-22 |
Family
ID=15218196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13827986A Pending JPS62294968A (en) | 1986-06-16 | 1986-06-16 | Diagnosing drug comprising monoclonal antibody |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62294968A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990007120A1 (en) * | 1988-12-19 | 1990-06-28 | The University Of Sydney | A new sandwich-elisa method for the detection and/or quantification of keratan sulphate peptides in biological fluids |
| WO1990006954A1 (en) * | 1988-12-19 | 1990-06-28 | The University Of Sydney | Monoclonal antibodies which recognise polysulphated polysaccharides |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60224065A (en) * | 1984-03-27 | 1985-11-08 | ラッシュ・プレズビタイアリアン・セント・ルークス・メディカル・センター | Method of diagnosing abnormality of cartilage tissue |
-
1986
- 1986-06-16 JP JP13827986A patent/JPS62294968A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60224065A (en) * | 1984-03-27 | 1985-11-08 | ラッシュ・プレズビタイアリアン・セント・ルークス・メディカル・センター | Method of diagnosing abnormality of cartilage tissue |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990007120A1 (en) * | 1988-12-19 | 1990-06-28 | The University Of Sydney | A new sandwich-elisa method for the detection and/or quantification of keratan sulphate peptides in biological fluids |
| WO1990006954A1 (en) * | 1988-12-19 | 1990-06-28 | The University Of Sydney | Monoclonal antibodies which recognise polysulphated polysaccharides |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Coon et al. | Blood group precursor T-antigen expression in human urinary bladder carcinoma | |
| JP5752688B2 (en) | Method and apparatus for antigen activation process | |
| JPS63500891A (en) | Method of facilitating and/or accelerating immunoassay of antigens associated with human carcinoma in pathological specimens | |
| CN105566499B (en) | A kind of polymer enzyme antibody and preparation method thereof | |
| JPS63502484A (en) | Method for characterizing cell origin tissue and/or cell abnormality | |
| EP0032204A1 (en) | Process and reagent for the immunological determination of enzymes | |
| CN112113821B (en) | Multiple staining slide preparation method of cytopathology sample | |
| Ruffolo et al. | Techniques for examining Pneumocystis carinii in fresh specimens | |
| JPS62294968A (en) | Diagnosing drug comprising monoclonal antibody | |
| JPH05508078A (en) | Analyzer and method for detecting chitin | |
| TWI753521B (en) | Composition and method for rendering biological material | |
| RU2455937C1 (en) | Method of detecting pseudoexfoliation material at early stages of eye disease | |
| Lloyd et al. | Silver-staining of senile plaques and neurofibrillary change in paraffin-embedded tissues | |
| EP1314038B1 (en) | Method for analysing stool specimens for diagnostic purposes | |
| Jafari et al. | Diagnostic value of immunoperoxidase staining and immunofluorescence in the study of kidney biopsy specimens | |
| Ramaekers et al. | The use of antibodies to intermediate filament proteins in the differential diagnosis of lymphoma versus metastatic carcinoma | |
| CN110954701A (en) | Diagnostic kit for hepatic fibrosis or cirrhosis | |
| CN110411813A (en) | A kind of method cell block sizing fixed plate and make cell block with it | |
| RU2725765C1 (en) | Method of staining antigens by means of fluorescent antibodies on fresh-frozen sections of tumour and metastases | |
| RU2691606C1 (en) | Method for detecting the presence of estrogen and progesterone receptors in tissue of her2-negative breast cancer | |
| RU2709608C1 (en) | Method for determining blood coagulation protein in animals | |
| US20170199194A1 (en) | Multi-phenotypic subtyping of biological samples using sequential fluorescent quenching and restaining | |
| Das et al. | Immunohistochemistry and its forensic importance | |
| CN108761067A (en) | The biomarker and application thereof of idiopathic inflammatory myopathies detection | |
| RU2627455C1 (en) | Method for manufacturing of biomechanical sensor for adhesion force measurement in "cell-cell" system |